Dr. Zhiwei Zhong’s research focuses on molecular oncology, nanomedicine, and biomarker discovery in complex diseases such as pancreatic cancer, hepatocellular carcinoma, thyroid eye disease, and venous thromboembolism. His studies integrate bioinformatics, molecular biology, and nanotechnology to uncover therapeutic targets and diagnostic biomarkers. Zhong has contributed to several high-impact publications in PLOS One, Cancer Cell International, Oncology Reports, Digestive Diseases and Sciences, and SN Applied Sciences. His notable works include identifying key extracellular proteins (EGFR, CD44, and CXCL8) as potential biomarkers in thyroid eye disease, elucidating the regulatory role of lncRNA FTX in suppressing NAFLD progression to hepatocellular carcinoma via Kupffer cell polarization, and exploring nanoparticle-based drug delivery systems for targeted thrombolysis and cancer therapy. He has also investigated tumor suppressor mechanisms involving KLF9 and CHD1L in pancreatic cancer, providing insights into tumor proliferation, invasion, and survival pathways. His research contributions advance the understanding of molecular pathogenesis, precision diagnostics, and targeted nanotherapeutic strategies in human diseases.
